The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Describe the structure of the erythropoietin receptor. Describe the function of the erythropoietin receptor. Describe the distributions of erythropoietin receptors in normal and tumor tissues. Access and take the CME test online and receive one hour of AMA PRA category 1 credit atCME.TheOncologist.com Erythropoietin (EPO) is the primary regulator of erythropoiesis, stimulating growth, preventing apoptosis, and promoting differentiation of red blood cell progenitors. The EPO receptor belongs to the cytokine receptor superfamily. Although the primary role of EPO is the regulation of red blood cell production, EPO and its receptor have been localized to several nonhematopoietic tissues and cells, including the central nervous system (CNS), endothelial cells, solid tumors, the liver, and the uterus. The presence of EPO receptors and the possibility of EPO signaling in these tissues and cells have led to numerous studies of the effects of EPO at these sites. In particular, expression of EPO and the EPO receptor in cancer cells has generated much interest because of concern that administration of recombinant human erythropoietin (rHuEPO) to patients with breast and other cancer cells expressing the EPO receptor may promote tumor growth via the induction of cell proliferation or angiogenesis. However, evidence supporting a growth-promoting effect has been inconclusive. Moreover, several preclinical studies have shown a beneficial effect of EPO on delaying tumor growth. Further, it is conceivable that increased expression of EPO could reduce tumor hypoxia and ameliorate the deleterious effects of hypoxia on tumor growth, metastasis, and treatment resistance. On the other hand, EPO has also been shown to produce an angiogenic effect in vascular endothelial cells in vitro. However, there is no evidence that these effects occur in vivo to promote tumor growth. EPO and EPO receptors are expressed in neural tissue, and they are upregulated there by hypoxia. Animal studies have shown that administration of epoetin alfa (an rHuEPO) reduces tissue injury due to ischemic stroke, blunt trauma, and experimental autoimmune encephalomyelitis. These findings suggest that epoetin alfa may provide a therapeutic benefit in patients with stroke, trauma, epilepsy, and other CNS-related disorders. Clearly, further study of EPO and the EPO receptor in nonhematopoietic tissue is warranted to determine the potential therapeutic usefulness of rHuEPO as well as to determine the signaling pathway responsible for its effect in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Cited by
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
Fishbane, S., & Berns, J. S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00532.x · Cited by 289
The role of iron in tumour cell proliferation
Steegmann-Olmedillas, J. L. (2011) · Clinical and Translational Oncology · doi:10.1007/s12094-011-0621-1 · Cited by 84
Metadata
- Authors
- Farrell, F., & Lee, A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-01
- Volume
- 9
- Issue
- S5
- Pages
- 18-30
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2128950429
- Cited by
- 191
- References
- 1
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues. https://app.cochat.ai/papers/10.1634/theoncologist.9-90005-18
- The paper
- Farrell, F., & Lee, A. (2004). The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues. The Oncologist. https://doi.org/10.1634/theoncologist.9-90005-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.